Summary. The effects of Ca 2+ and calcitonin infusions on circulating glucagon, glucose, C-peptide, Ca 2+, and calcitonin were investigated in hyperglucagonaemic insulin-dependent diabetics. In 14 insulin-deprived diabetics and 12 healthy volunteers 2 h infusions of saline (0.154 tool/l), Ca 2+ (0.375 mmol/kg body weight), and ealcitonin (4.5 IU/kg body weight) were performed. There were no significant changes during saline infusion. In the diabetics, Ca 2+ infusions induced a rise of plasma Ca 2+ up to 3.2 _ 0.1 mmol/1 and a fall of circulating glucagon (--26.4 +_ 5.7%; p < 0.001) and glucose (-23.3 _+ 3.6%; p < 0.05). Plasma calcitonin rose to twice basal values (p < 0.025). During calcitonin infusions plasma Ca 2+ decreased slightly to 2.1 + 0.2 mmol/1; a fall was found in both glucose (-24.4 _+ 4.0%; p < 0.05) and circulating glucagon (-22.5 +_ 4.3%; p < 0.001), Two groups of 6 healthy volunteers were subjected to saline and Ca 2+, or to Ca 2+ and calcitonin infusions. Both Ca 2+ and calcitonin infusions induced a fall of serum insulin (-30.1 + 6.6%; p < 0.05). Calcitonin depressed circulating glucagon by -18.6 +_ 4.4% (p < 0.025), whereas during Ca 2+ infusions glucagon decreased only by -6,5 _+ 1.9% (p > 0.1). We conclude from our results that an increase of circulating calcitonin induced by Ca 2+ infusions or by exogenous calcitonin administration appears to depress elevated circulating glucagon and glucose in insulin-dependent diabetics.
Recently we have demonstrated in healthy subjects that Ca 2+ infusions lower the plasma glucagon levels stimulated by arginine or insulin-induced hypoglycaemia. Ca 2+ was, however, ineffective in altering basal circulating glucagon levels to a significant extent [1] . In insulin-dependent diabetics the basal levels of circulating glucagon are often found to be elevated [2, 3, 4, 5] . It is known that a stimulated calcitonin release from the thyroid gland is found during Ca 2+ administration [6] . In the present study we have therefore investigated the effects of Ca 2+ and calcitonin infusions on circulating glucagon levels and elevated blood glucose concentrations in insulindependent diabetics following a 12 hour period of insulin-withdrawal.
Materials and Methods
Fourteen patients with insulin-dependent diabetes mellitus (clinical data and mean baseline values on the day of experiment are shown in Table 1 ) who had been treated with two daily injections of intermediate long-acting insulin and one morning dose of regular insulin and a weight-maintaining diet in our metabolic ward for about ten days were chosen for the study. The patients were free of coronary heart disease, had no signs of cardiac failure, and were shown to have a normal creatinine clearance as well as normal basal plasma Ca 2+. In addition, 12 normal subjects, matched for age, sex, and body weight were examined. They all gave their informed consent to participate in the study which was carried out according to the principles of the declaration of Helsinki.
Tests were performed after an overnight fast in 14 insulindependent diabetics who had received their last usual insulin injection 24 h before the tests. On the morning of investigation, two Teflon catheters were inserted into contralateral antecubital veins; one was kept patent by an infusion of 0.154 mol/1 saline, the other was used to infuse over 2 hours 0.375 mmot/kg body weight of Ca 2+ as a 200 g/1 solution of calcium gluconate (n = 7) or 4.5 IU/ kg body weight of salmon calcitonin dissolved in 30 ml of saline (n = 4) using an infusion pump (Braun-Melsungen, West Germany). The total infused volume during the experimental period of 300 min did not exceed 250 ml. An equivalent volume of 250 ml of 0.154 tool/1 saline was infused in 5 patients as control. Blood samples were drawn at indicated time intervals up to 300 rain after the onset of the infusions and immediately discharged into refrigerated tubes containing t000 U of TrasyloI and 1.2 mg of Na2EDTA/ml of blood for glucagon and calcitonin immunoassays.
Six healthy volunteers were subjected to saline and Ca 2+ infusions on two different days under the same conditions as the dia- Table 1 . Clinical data and baseline values of insulin-dependent diabetic and healthy control subjects on the day of saline (NaC1), Ca 2+, or calcitonin infusion. Mean _+ SD and the range of mean daily insulin dosage, plasma C-peptide, and plasma glucagon (diabetics) are given. betic subjects. Six other volunteers received an infusion of 0.375 mmol/kg body weight of Ca 2+ as calcium gluconate and an infusion of 4.5 IU/kg body weight of porcine calcitonin within 2 h on two different days. Blood samples were drawn before and 120 min after the onset of infusions. Plasma Ca 2+ was measured by atomic absorption; blood gincose enzymatically; serum insulin, plasma C-peptide, plasma glucagon [7, 8] , and plasma calcitonin [9] were measured by immunoassay. Plasma glucagon was assayed using the antibody 30 K (pool 4, lot 3, 1978) , kindly provided by Dr. R. Linger, Dallas, Texas. The charcoal dextran separation technique was performed. The limit of sensitivity of the glucagon immunoassay was 20 ng/1 at the 97.5% confidence limit; the interassay coefficient of variation was 20% at a concentration of 40 ng/1 and 12.5% at 115 ng/1. Calcitonin was assayed using a commercially available kit system (RIA-mat calcitonin, Byk-Mallinckrodt, West Germany). The antiserum in this system was raised in a goat against synthetic human calcitonin according to Dietrich et al. [9] . The doubleantibody separation technique was used in tbe presence of polyethylene glycol. Standards were made up in calcitonin-free human serum prepared by florisil extraction. Salmon and porcine calcitonin are not detectable in this assay. The sensitivity of the calcitonin immunoassay was 50 ng/l; the interassay coefficient of variation was 10% at a concentration of 500 ng/l. Data in the text, tables and figure are given as mean _+ SEM unless otherwise indicated (Table 1 : mean _+ SD). Standard statistical methods have been employed using Student's paired and unpaired t-tests.
Results
Basal circulating plasma glucagon levels were significantly higher in the diabetic patients (112 + 16 ng/1 in the entire group of 14 diabetics; range 38-295 ng/1) than in normal volunteers (69 + 5 ng/1; range 44-115 ng/1; n = 12; p < 0.025).
Saline Infusions
In normal subjects (n = 6) saline infusions had no significant effect on any of the hormones or metabolites measured. Plasma glucagon remained constant at 50 _+ 9 ng/1; serum insulin at 9.6+1.8 mUff; Ca :+ at 2.3 + 0.1 mmol/1. In the diabetic patients, blood glucose was 11.9 + 1.0 mmol/1 in the basal state and 13.3 + 1.7 mmol/1 at the end of the experimental period after 300 min, whereas plasma Ca 2+, circulating glucagon, and C-peptide remained unchanged Tables 1, 2 A low basal plasma C-peptide appeared to decrease further throughout the experimental period. Five hours after the onset of Ca 2+ infusions, the calcitonin and glucagon levels had returned of the basal range (Table 2 and Fig. 1 ).
Calcitonin Infusions
During calcitonin infusions plasma Ca 2+ showed no significant change (2.4 + 0.2 to 2.1 + 0.1 mmol/1), remaining within the normal range in normal and diabetic subjects. A 2 h infusion of calcitonin in six normal subjects caused a fall in serum insulin (from 6.9 + 1.0 to 4.9 _+ 1.5 mU/1; p < 0.01) and plasma glucagon (from 85 + 9 to 69 + 9 ng/1; p < 0.025) whereas blood glucose increased from 5.2 _+ 0.2 to 7.0 _+ 0.3 mmol/1 (p < 0.001). In this group, control studies with Ca 2+ infusions caused a fall in serum Table 4 . Effect of calcitonin infusions (4.5 IU/kg) on circulating levels of Ca 2+, glucagon, and glucose in insulin-dependent diabetics (n = 4). Means _+ SEM are given; symbols as in Table 2 Time insulin from 5.4 _+ 0.5 to 3.9 + 0.4mU/l (p < 0.025); plasma glucagon levels showed no significant change (77 + 9 to 73 _+ 9 ng/1), but this was significantly different when compared with the calcitonin infusions. Blood glucose levels remained unchanged. These data are summarized in Table 3 . In the diabetic patients, blood glucose levels decreased significantly during calcitonin infusions by -24.4 4-4.0% (p < 0.05); plasma glucagon fell significantly 30 rain after the onset of calcitonin infusions by -22.5 + 4.3% of the mean baseline values (p < 0.001) and remained at this level throughout the 2 h infusion of calcitonin. The effect of calcitonin infusions on blood glucose and plasma glucagon levels was similar to the effect of Ca 2+ administration. The initial decrease of circulating glucagon was more pronounced during exogenous calcitonin infusions than during Ca 2+ administration, however. Five hours after the onset of infusions plasma glucagon had returned to the basal values (Table 4 and Fig. 1 ).
Discussion
Since Unger and Orci re-emphasised the hypothesis of the bihormonal nature of the metabolic disturbances in diabetes mellitus [10] , several attempts have been made to normalise hyperglycaemia in insulindependent diabetics by an inhibition of pancreatic glucagon secretion [11] . Thus, somatostatin [12, 13] , somatostatin analogues [14] as well as anti-inflammatory drugs [15] have been shown to improve acutely metabolic disturbances in diabetic patients presumably due to a decrease in circulating glucagon levels.
In seven insulin-dependent diabetics 24 h after their last insulin injection a temporary hypercalcaemia associated with a substantial rise of plasma calcitonin induced a significant fall of plasma glucagon and blood glucose concentrations. The same effect on blood glucose and glucagon levels was found during calcitonin administration at normal plasma Ca 2+ ; the initial decrease of circulating glucagon was more pronounced during calcitonin infusions. We were unable to determine the plasma concentrations of exogenous calcitonin because our calcitonin immunoassay was only sensitive to human calcitonin. However, although the amount of caMtonin administered in this study was of a magnitude to give rise to blood concentrations well above the physiological range on the basis of approximations of the pharmacokinetics [16] , we found the effects on blood glucose and circulating glucagon within a similar range as during endogenous calcitonin stimulation due to hypercalcaemia. Our plasma glucagon levels determined with the antibody 30 K represent total glucagon immunoreactivity (IRG). Therefore we are unable to assess if pancreatic glucagon (IRG 35~176 is altered during Ca 2+ or calcitonin infusions.
Previously we have demonstrated in normal subjects that Ca :+ infusions, which induced a rise in plasma caMtonin levels, inhibited the arginine-and hypoglycaemia-induced stimulation of glucagon release [1] . In addition, even the low basal plasma glucagon levels in healthy subjects were significantly decreased during calcitonin infusions in this study.
It is known that calcitonin inhibits gastric and exocrine pancreatic secretion as well as the secTetion of insulin [17, 18] . Calcitonin reduces glucoseinduced insulin secretion [19] as well as argininestimulated insulin secretion [20] in normal man. No data on glucagon secretion were reported in these studies. Ohneda et al. [21] and Tamarit et al. [22] demonstrated a suppressive effect of Ca 2+ administration on glucagon secretion in dogs in vivo but different antibodies were used for glucagon immunoassays in these studies. Although data concerning calcitonin levels during Ca 2+ administration in these in vivo studies are not reported the results are in accordance with our findings in diabetics and normal man when extracellular Ca z+ levels were elevated. It is assumed that calcitonin exerts its inhibitory effect on hormone release via a stimulated Ca 2+ efflux from the cells and intracellular movements of Ca 2+, that is a decrease of cytosolic Ca 2+ content and an enhancement of mitochondrial Ca 2+ content [17, 23, 24, 25, 26] .
Effects of extracellular Ca 2+ concentrations on glucagon release in vitro from the perfused isolated rat pancreas have been reported by Leclercq-Meyer et al. [27, 28] . Omission of Ca 2+ from the peffusion medium induced a significant enhancement of glucagon release whereas elevated extracellular Ca 2+ concentrations of 4 mmol/1 did not modify the glucagon release in the absence of caleitonin. On the other hand, in the perfused rat pancreas calcitonin failed to inhibit glucagon release during rising glucose concentrations [29] .
The important role of Ca 2+ in the stimulus-secretion coupling mechanisms of hormone release is generally accepted though the precise mechanisms concerning glucagon release are still not completely worked out: The presence of extracellular Ca 2+ ions is required for an adaequate glucagon release [28, 30] and high glucose concentrations fail to inhibit glucagon release in the absence of Ca 2+ in the perfusion mediums [28, 31] . Inhibited Ca 2+ uptake of the a-cells by verapamil is associated with decreased glucagon release during certain stimulatory conditions in vitro. Thus, in addition to the presence of extracelltflar Ca 2+ ions per se, the a-cell requires the integrity of inward Ca 2+ transport [32, 33] .
In normal volunteers, calcitonin infusions induced a significant decrease of circulating glucagon levels whereas Ca 2+ administration did not depress normal basal glucagon levels significantly. Because of a substantial decrease of serum insulin during both Ca 2+ and calcitonin infusions, the effects of the glucagon depression on blood glucose levels were masked. In insulin-deprived diabetics, we have demonstrated a progressive fall of blood glucose during Ca 2+ administration, perhaps as a consequence of a decrease of the elevated circulating glucagon levels. During Ca 2+ infusions, however, there was an increase of both plasma Ca 2+ and plasma calcitonin levels. In order to differentiate whether only direct effects of elevated extracellular Ca 2+ or the rise in plasma calcitonin were responsible for the inhibition of glucagon secretion under those circumstances we have infused calcitonin in 4 insulin-dependent diabetics: there was a substantial fall of both, blood glucose and plasma glucagon, whereas Ca 2+ remained unchanged. Thus, we suggest that an increase of circulating calcitonin levels induced by Ca 2+ infusions or by exogenous calcitonin administration appears to depress elevated circulating glucagon and glucose levels in insulin-dependent diabetics.
